What are cultured mesenchymal cells (CMC)?
What cultured mesenchymal cells (CMC) are, why they are regulated as an advanced therapy medicinal product and what ITRT’s published clinical evidence shows.
International patients at Teknon Hospital in Barcelona: what to know before considering an advanced cell therapy medicinal product
Teknon Hospital in Barcelona: what international patients should know before considering an advanced cell therapy medicinal product with cultured mesenchymal cells (CMC). We explain what the AEMPS requires, what documentation ITRT reviews remotely (MRI and medical history), and how consultations are organized at Centro Médico Teknon.
Herniated disc without nerve compression: is there a treatment that structurally regenerates the intervertebral disc?
When a herniated disc does not compress any nerve root, physical therapy and surgery relieve the symptom but do not act on the disc. What the scientific evidence says about structural regeneration of the intervertebral disc with Cultured Mesenchymal Cells (CMC), and which questions remain open.
Rotator cuff: what the evidence shows, and what an advanced cell therapy medicine with cultured MSCs (CMC) actually is
A rotator cuff tear (usually of the supraspinatus tendon) does not always respond to physical therapy and corticosteroid injections. We review what the scientific evidence says and what distinguishes, from a regulatory standpoint, an advanced cell therapy medicine with cultured mesenchymal cells (CMC) from a same-day cell concentrate.
Why does the Achilles tendon hurt and how to treat the pain?
We review the causes of Achilles tendon pain, the most common types of injury, and available treatment options — from conservative management to advanced cell therapy medicinal products with CMC.
Knee osteoarthritis: when surgery isn’t your only option
Is surgery the only option for advanced knee osteoarthritis? We review what gonarthrosis is, what the clinical evidence shows on cultured mesenchymal cells (CMC), and what requirements ITRT applies when evaluating alternatives authorized by the AEMPS.
The role of AEMPS in advanced cell therapy drugs
The AEMPS supervises the full lifecycle of advanced cell therapy medicinal products with cultured mesenchymal cells (CMC): clinical trials, GMP manufacturing, clinical application, and pharmacovigilance.
Chronic patellar tendinopathy: what sets cultured mesenchymal cells (CMC) apart from PRP?
Chronic patellar tendinopathy that does not respond to conventional treatments now has a clinical alternative backed by evidence: cultured mesenchymal cells (CMC). We explain what sets them apart from PRP and why the distinction matters.
Cellular dose in cultured mesenchymal cells (CMC): why it is the parameter that changes everything
Before undergoing any procedure involving mesenchymal cells, there is one question that should be answerable with documentation: how many cells will be administered, and how has that number been verified? If no concrete answer exists, the procedure is not classified as a regulated medicinal product. The cellular dose is the technical and regulatory criterion that marks that difference. In this article, we explain how it is defined, how it is certified, and why it is decisive in indications such as tendons, cartilage, and lumbar disc disease, from the clinical and scientific perspective of ITRT.